-
2025-522338-30-00
4
2026-03-31
Ulcerative Colitis
-
2025-522046-42-00
5
2026-03-24
Colonic disease
-
2024-518777-34-00
5
2026-02-11
B7-H4-Selected Advanced/Metastatic Endometrial Cancer.
-
2025-521873-15-00
9
2026-02-09
Metastatic hormone-sensitive prostate cancer
-
2025-522960-34-00
5
2026-02-09
Established cardiovascular disease
-
2025-521917-24-00
5
2026-01-21
Treatment-Naïve Recurrent/Metastatic Head and Neck Squamous Cell Carci
-
2025-523620-44-02
6
2026-01-20
non small cell lung cancer (NSCLC)
-
2024-512298-28-00
11
2025-12-18
Neovascular age-related macular degeneration
-
2025-520825-19-00
5
2025-12-16
IgAN is Primary Immunoglobulin A Nephropathy (IgAN) (also known as
Ber
-
2024-514500-14-00
5
2025-12-15
Participants with KRAS G12C-Mutant, Advanced or Metastatic Nonsquamous
-
2024-520164-33-00
5
2025-12-09
Non-Small Cell Lung Cancer
-
2025-521349-25-00
5
2025-12-09
Macular neovascularization secondary to age-related macular degenerati
-
2025-521382-27-00
10
2025-12-04
Moderately to Severely Active Crohn's Disease
-
2025-521381-10-00
5
2025-12-03
Moderately to Severely Active Ulcerative Colitis
-
2024-512577-27-00
5
2025-12-02
Chronic kidney disease in paediatric patients
-
2025-521242-26-00
4
2025-11-27
Moderately to Severely Active Ulcerative Colitis
-
2024-517091-38-00
3
2025-11-25
Head and neck squamous cell carcinoma
-
2025-521511-40-00
10
2025-11-18
metastatic non-small cell lung cancer
-
2024-515979-35-00
5
2025-11-13
Generalized Myasthenia Gravis
-
2024-518206-40-00
5
2025-11-03
Severe hypertriglyceridemia (SHTG)
-
2024-519917-72-00
5
2025-10-29
Transthyretin Amyloidosis with Cardiomyopathy (ATTR Amyloidosis with C
-
2024-518365-10-00
5
2025-10-28
Previously Untreated Advanced or Metastatic Non-Squamous Non−Small Cel
-
2024-519081-49-00
4
2025-10-28
Moderate to severe atopic dermatitis
-
2024-519495-83-00
4
2025-10-28
Digestive system diseases